Report On Prescribing Data Restriction Program (PDRP) Available

 

Prescribing Data Restriction Program (PDRP) Report Available from Piribo

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has just added to its collection a key market report on the Prescribing Data Restriction Program.

(PRWEB) September 15, 2006 -- Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has just added to its collection a key market report on the Prescribing Data Restriction Program.

Since the mid-1990s, pharma companies have devised their sales and marketing strategies based on Rx data. However, with the introduction of the AMA's Prescribing Data Restriction Program (PDRP) opt-out program in July 2006, pharma companies need to evaluate the impact of PDRP violation, mediate their PDRP compliance strategies, and revisit their existing Sales Force Effectiveness (SFE) practices. With the introduction of the PDRP, the use of physician Rx data by pharmaceutical companies will never be the same again. The PDRP prohibits access to physician-level Rx data, which directly impacts First Line Managers, Sales Representatives, and anyone else that accesses or distributes physician Rx data.

The Prescribing Data Restriction Program: Critical Assessment and Best Practices (http://www.piribo.com/search/results.html?k=arr014&x=0&y=0) estimates the impact of PDRP violations, analyzes the use of Rx data, gauges awareness in the marketplace and benchmarks the best practices towards PDRP compliance.

Table of Contents:
Objective and Methodology
Methodology
Abbreviations
Key takeaways

1 Executive Summary
1.1 Mixed responses towards compliance
1.2 PDRP impacts all pharma companies
1.3 Critical success factor
1.4 Best practice of pharma companies’ PDRP compliance strategies - mix of standard operating practices and
technology

2 Introduction
2.1 PDRP definition from AMA
2.2 About the PDRP and need to adopt best practices
2.3 Very low awareness of the PDRP
2.4 Impact of Sales Rep's and DM's lack of access to Rx data
2.5 Finding the right balance in implementing PDRP compliance strategies
2.6 There are currently no recommended best practices for PDRP compliance
2.7 Legislators observing PDRP compliance closely
2.8 Compelling reasons for pharma companies to comply with the PDRP
2.8.1 Avoiding negative publicity is key motive for PDRP compliance
2.8.2 Loss of Rx data

3 Impact of the PDRP on pharma companies
3.1 Pharma companies underestimate the impact of the PDRP
3.2 All pharma companies will be impacted by the PDRP
3.3 PDRP can increase sales and marketing costs by 20%
3.4 Risk of ineffectiveness in the sales force in absence of Rx data - highest loss component
3.5 Impact of the PDRP on competitive edge

4 Critical success factors for complying with the PDRP
4.1 Use and blocking of Rx data
4.2 The issue of reverse engineering
4.3 Changes in technology and systems are a must to comply with the PDRP
4.4 Technology solution
4.5 Existing SFE strategies
4.6 Time and cost of implementation
4.7 Balancing PDRP compliance and the need for a competitive edge
4.8 Defense strategy
4.9 Issues and challenges
5 Best practices towards PDRP compliance
5.1 Best standard operating practices by pharma companies
5.1.1 SFE planning and execution
5.1.2 SFE planning department - senior managers not interacting with physicians
5.1.3 SFE planning department to perform targeting and segmentation
5.1.4 SFE execution department - Sales Rep and DM
5.1.5 Benefits of the above model
5.2 Incentive structure
5.2.1 Option 1
5.2.2 Option 2
5.2.3 Option 3
5.3 Pull-through strategies
5.4 Important parameters to determine the top prescribing physicians within the influential plans
5.4.1 A few more SOPs towards PDRP compliance
5.5 Sales Reps, DMs and PDRP compliance
5.5.1 Training of Sales Reps
5.5.2 Sales Reps' use of Rx data
5.5.3 Sales Reps and the reverse engineering of data
5.5.4 Sales Reps understanding of the "Big Picture"
5.5.5 Sales Rep employee contracts: Redefined?
5.5.6 Sales Reps and market intelligence
5.6 Technology priorities to comply with the PDRP
5.6.1 SFA/CRM systems
5.6.2 Security of reports
5.6.3 Rx details in incentive slips
5.6.4 New technology solutions?
5.6.5 Apt PDRP compliance strategies pay off
5.6.6 Pharma companies' perceptions of cost of PDRP compliance
5.6.7 Time allowance for PDRP compliance
5.8 Foolproof defense strategies
6 Conclusions: Roadmap to PDRP compliance
6.1 Best Practices
6.2.1 SFE planning and SFE execution
6.2.2 New use of target lists
6.2.3 "Pre-calling", "During calls" and "Post calls"
6.2.4 Sales Rep training
6.2.5 Incentive calculations
6.2.6 SFE/CRM technology solutions

“The Prescribing Data Restriction Program - Critical Assessment and Best Practices” is available in PDF format from Piribo. For more information, go to: http://www.piribo.com/publications/regulation_policy/prescribing_data_ 
 restriction_programcritical_assessment_practices.html

About Piribo
Piribo is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.

###

Press Contact: Brendt Sheen
Company Name: PIRIBO LTD
Email: email protected from spam bots
Phone: 02070607474
Website: http://www.piribo.com/publications/regulation_policy/prescribing_data_restriction_programcritical_as